Date: 2015-11-30
Type of information: Nomination
Compound:
Company: Ablynx (Belgium)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On November 30, 2015, Ablynx announced the appointment of Robert K. Zeldin, MD, as Chief Medical Officer (CMO). Effective from 1 December 2015, Dr Zeldin will lead the Company\'s global clinical development, regulatory and medical affairs activities. Dr Zeldin brings significant industry experience to the Company, having held senior level clinical development positions at top tier pharmaceutical companies, including Merck & Co and Novartis. In his previous roles, Dr Zeldin headed teams in immunology, respiratory, dermatology and cardiovascular disease where he was responsible for clinical development through to commercialisation and life cycle management. He also successfully engaged key stakeholders including the scientific community, payers, patient advocacy groups and key opinion leaders.
Prior to his move into the pharmaceutical industry, Dr Zeldin spent several years in private practice and two years as a Medical Officer at the FDA\'s Center for Biologics Evaluation and Research. There he evaluated safety and efficacy data from all phases of clinical development. Dr Zeldin holds a Medical Doctor degree from the Tufts University School of Medicine, Boston, USA. He completed Internship and Residency in Internal Medicine at the University Health Center of Pittsburgh and Fellowship in Allergy & Clinical Immunology at the Johns Hopkins University School of Medicine. Dr Zeldin replaces Dr Dominique Tersago as CMO.
Financial terms:
Latest news:
